Xactus Now Offering PayNet's Credit History Reports itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Putting Australian clinical research on the map globally, comes the ground-breaking first-in-human clinical trial for KIO-301. MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ In collaboration with US-based Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and The Royal Adelaide Hospital, leading Australian CRO, Accelagen, is proud to announce that dosing has commenced in the Phase 1 first-in-human trial for KIO-301. This trial represents a remarkable development in the treatment of people with the rare inherited condition, Retinitis Pigmentosa (RP), which currently has no approved cure or standard treatment. Always at the forefront of full service pharmaceutical and medical device development worldwide, Accelagen's work is first and foremost about accelerating and improving the future of human health: "Clinical research is not about just testing something in a group of trial participants. It is about creating measurable improvements for people's health and wellbeing that will
/PRNewswire/ In collaboration with US-based Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and The Royal Adelaide Hospital, leading Australian CRO, Accelagen,.
EQS-News: Vakzine Projekt Management GmbH / Key word(s): Study results VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG 25.01.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. VPM ov.
EQS-News: Vakzine Projekt Management GmbH / Key word(s): Study results VPM oversees clinical trial and translational project management - Positive Phase I data of client Memo Therapeutics